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ORIGINAL ARTICLE
Osteoarthritis (OA) is the most common form of
chronic joint disorder worldwide. In OA of the
knee, pathogenic changes result in cartilage ero-
sion, meniscal degenerative tears, subchondral
bone remodeling, osteophyte formation, and
synovial inflammation.1 According to the recom-
mendations of the American College of Rheuma-
tology (ACR) for knee OA, the primary goals for
contemporary management include control of
pain and improvement in function and health-
related quality of life, with avoidance, if possible,
of toxic effects of therapy.2 If noninvasive or non-
operative treatment is not indicated, is ineffec-
tive, or is not tolerated, intra-articular injection
with steroids or hyaluronan (hyaluronic acid; HA)
is considered.2,3
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Hylan G-F 20 Has Better Pain Relief and 
Cost-effectiveness than Sodium Hyaluronate
in Treating Early Osteoarthritic Knees 
in Taiwan
Chi-Wen Chou,1 Ko-Huang Lue,2 Hong-Shen Lee,3 Renn-Chia Lin,1 Ko-Hsiu Lu1,2*
Background/Purpose: Intra-articular injection of hyaluronan (hyaluronic acid; HA) products is available to
treat early osteoarthritis (OA) of the knee in Taiwan. We tested whether HA products with different molecular
weights have significantly different effects on clinical efficacy and cost-effectiveness.
Methods: Thirty-seven patients with mild to moderate OA of both knees underwent five weekly intra-articular
injections of sodium hyaluronate (Artz®) in one knee and three weekly intra-articular injections of chem-
ically cross-linked Hylan G-F 20 (Synvisc®) in the other. Visual analog scale (VAS), Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC), Lequesne’s index, and Hospital for Special Surgery
(HSS) knee scores were compared initially and at the last injection, and at 8, 12, 16, 20, and 26 weeks after
the first injection.
Results: VAS, WOMAC, WOMAC-A1 (pain when walking on a flat surface) scores before week 16, HSS
scores before week 12, and Lequesne’s index scores except at week 26 all showed that HA significantly im-
proved the scores time-dependently. In VAS scores, Synvisc® showed better improvement before week 20,
while this effect appeared at week 12 for the WOMAC-A1 scores. The incremental cost-effectiveness ratio
of the Taiwan National Health Insurance Program, of the patient, and both of these was lower for Synvisc®,
which also reduced the number of additional hospital visits for injections by two.
Conclusion: Synvisc® possesses better symptom-modifying ability and cost–utility in treating early OA of
the knee in Taiwan. [J Formos Med Assoc 2009;108(8):663–672]
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Injecting exogenous HA into the knee joint
can enhance chondrocyte HA and proteoglycan
synthesis, reduce the production and activity of
pro-inflammatory mediators, urokinase-type plas-
minogen activator (u-PA), plasminogen activator
inhibitor-1 (PAI-1), and matrix metalloprotein-
ases (MMPs), and alter the behavior of immune
cells.4–7 Exogenous HA is also known to inhibit
nitric oxide production,8 delay degradation of
cartilage by inhibiting glycosaminoglycan release
from cartilage tissue,9 and have anti-inflammatory
effects.10 This efficacy might be related to the rhe-
ological properties and different molecular weight
(MW), which enhance penetration through the
extracellular matrix or promote binding to spe-
cific cell receptors, such as cluster determinants
(CDs).11,12
Currently, sodium hyaluronate (MW = 600–
1200 kDa; Artz®; Seikagaku Corp., Tokyo, Japan)
and chemically-cross-linked Hylan G-F 20 (MW =
6000 kDa; Synvisc®; Genzyme Biosurgery, Ridge-
field, NJ, USA) are available in Asia, the European
Union, and the United States. The MW of Artz® is
much lower than that of HA in normal healthy
synovial fluid.11 Synvisc® has been developed to
yield solutions with greatly enhanced elastovis-
cous properties like those in the knee joints of
healthy young adults (18–27 years of age), and
to prolong its intra-articular residence time to
improve the efficacy of viscosupplementation
therapy of OA.
The true outcomes in clinical viscosupple-
mentation with HA are difficult to determine,
because most investigators have used nebulous
inclusion criteria, inadequate study designs, short-
term follow-up times, and limited outcome-based
analyses, and have ignored safety and cost-effec-
tiveness.13–18 In OA, there is a hypercoagulable
and prothrombotic state with hypofibrinolysis,
and indirect evidence of increased fibrin genera-
tion,19 while HA with a high MW provides greater
inhibition of proteolysis and fibrinolysis.20,21 We
have also found that Synvisc® can downregulate
the expression of u-PA and PAI-1 and their down-
stream enzymes MMP-2 and MMP-9 more effec-
tively than Artz® can.5 These effects seem to
contribute, at least in part, to the apparent irre-
versibility of the OA disease process.
In Taiwan, treatment of mild-to-moderate OA
of the knee with either Artz® or Synvisc® is cov-
ered by the National Health Insurance Program.
Therefore, we tested the hypothesis that Synvisc®
has greater clinical efficacy than Artz®, and also
whether Synvisc® is more cost-effective than
Artz®.
Methods
Patients
Under the Taiwan National Health Insurance
Program, treatment of mild-to-moderate knee OA
with HA, such as five weekly intra-articular injec-
tions of Artz® from 1999, or three weekly intra-
articular injections of Synvisc® from 2005 was
indicated for patients who did not have adequate
pain relief despite conservative treatment with
oral analgesics or nonsteroidal anti-inflammatory
drugs (NSAIDs), exercise and physical therapy,
and whose knees were not affected sufficiently to
warrant total joint replacement. From October
2005 to June 2006, patients with symptomatic,
mild-to-moderate OA of both knees, who met
the inclusion criteria, were included in this study.
The inclusion criteria were ambulatory patients
aged ≥ 55 years with primary OA of both knees,
who fulfilled the ACR criteria22 and corresponded
to stage I–III in the Ahlback classification sys-
tem.23 In each case, the diagnosis was confirmed
with weight-bearing anteroposterior, lateral and
Merchant’s X-rays of both knees. We also en-
rolled patients who feared the deleterious effects
of long-term use of oral analgesics and NSAIDs.
The exclusion criteria were: treatment with steroids
or HA preparations within the past 6 months;
significant effusions in the knee; previous intra-
articular fractures of the knee; inflammatory joint
disease as defined by ACR criteria; joint infection;
chicken or egg allergy, or poor skin conditions
over the joint area, which may cause the adminis-
tration of injections to be problematic. This study
was conducted in accordance with the principles
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embodied in the Declaration of Helsinki and all
the patients gave informed consent.
Study design
Based on Student’s t tests with a probability level
of 5%, assuming a standard deviation of 30 mm,
a significance level of p=0.05, and a power of 0.80,
the sample size calculations indicated that 32 pa-
tients (64 knees) would be sufficient to detect a
difference of 15 mm in visual analog scale (VAS)
scores. Therefore, 41 patients were enrolled to allow
for dropouts. Patients with OA of both knees 
underwent five weekly intra-articular injections
of sodium hyaluronate (Artz®; Seikagaku Corp.)
in one knee and three weekly intra-articular in-
jections of Hylan G-F 20 (Synvisc®; Genzyme
Biosurgery) in the other. All injections were per-
formed by the same clinician. The outcome vari-
ables were recorded prior to participation, at 5
weeks for Artz® or 3 weeks for Synvisc® (the final
injection), and at 8, 12, 16, 20 and 26 weeks after
the first injection. No concomitant analgesics,
NSAIDs or steroids were administered (Figure 1).
Outcome measurement
We documented the outcome variables using
global 100 mm VAS, Western Ontario and
McMaster Universities Osteoarthritis Index
(WOMAC), Lequesne’s index, and Hospital for
Special Surgery (HSS) knee score criteria, initially
and at each follow-up. The VAS pain score was
evaluated for relief of knee pain. The WOMAC
score was patient-administered and assessed the
three dimensions of pain, stiffness and physical
function of the knee, using a battery of 24 ques-
tions, and a total score was provided. WOMAC-
A1 was the score of walking on a flat surface.
Lequesne’s index provided scores for pain, maxi-
mal walking distance and the activities of daily
living, and the maximum score was 26. The HSS
score was composed of seven classifications:
pain, function, range of motion, muscle strength,
flexion deformity, instability and subtractions,
with a total of 100 points. We measured and
compared the differences of the degree of im-
provement between Artz®- and Synvisc®-treated
groups.
Hylan has better efficacy and QALY gain
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41 patients were enrolled
5 weekly intra-articular
injections of Artz® in
one knee
3 weekly intra-articular
injections of Synvisc® in
the other knee
VAS, WOMAC, Lequesne’s index and HSS knee score
were recorded initially and at the last injection, and
at 8, 12, 16, 20 and 26 weeks after the first injection
Inclusion criteria:
 Ambulatory patients aged ≥ 55 years with primary OA of
 both knees fulfilling the ACR criteria and corresponding
 to stage I–III in the Ahlback classification system
Exclusion criteria:
 Treatment with steroids or HA preparations within the
 past 6 months, significant effusions in the knee, previous
 intra-articular fracture of the knee, inflammatory joint
 disease as defined by ACR criteria, joint infection,
 chicken or egg allergy or poor skin condition over the
 joint area which may cause the administration of
 injections to be problematic
4 patients withdrew
37 patients completed the 6 months’ follow-up
Figure 1. Study profile. OA=osteoarthritis; ACR=American College of Rheumatology; HA=hyaluronic acid; VAS=visual ana-
log scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; HSS = Hospital for Special Surgery.
Utility measurement
The quality-adjusted life year (QALY) was used
as the unit of outcome in the cost-effectiveness
analysis. A QALY is a composite index that in-
cludes effects in terms of both quality of life
(utility) and the duration of time in such a health
state. We analyzed the cost–utility between Artz®
and Synvisc® injections by calculating the QALY
from the baseline to 26 weeks (0.5 years) to eval-
uate the cost-effectiveness. Utility was derived 
from the transformed VAS
for general health, where a weight of 1 corre-
sponded to 0 of the VAS score (best state of
health), and a weight of 0 to a state of 100 of the
VAS score (worst state of health). For the utility of
Artz® or Synvisc®, there were seven therapeutic
values (known points) on the curve. We assumed
it was a graph of function expressed by a polyno-
mial of degree six determined by seven given
points, including the baseline point. The function
f(x) we obtained was an approximate equation
of the curve, where x was time (baseline to 0.5
years), and f(x) was the utility. Accordingly, each
patient had two curves for the utility for Artz®
and Synvisc®: fAn(x)=aAnx6 +bAnx5 + cAnx4 +dAnx3 +
eAnx2 + fAnx + gAn and fSn(x) = aSnx6 + bSnx5 + cSnx4 +
dSnx3 + eSnx2 + fSnx + gSn (A = Artz®; S = Synvisc®;
n = 1–37). We substituted the value of each point
for f(x) and x, thus giving seven simultaneous
equations and obtained values for a, b, c, d, e, f
and g of each curve by solving the set of simulta-
neous equations. The area between the curve of
utility and the equation of the baseline [fAn(0) =
gAn and fSn(0) = gSn] could be calculated by the
integration of fAn(x) and fSn(x) with respect to x,
to define the quality of life per period from the
baseline to 0.5 years. There were 37 paired qual-
ity of life values per period for Artz® and Synvisc®
obtained and (QALYs) was expressed by the 
results:24 and
. We then cal-
culated the incremental cost-effectiveness ratio 
(ICER) by dividing (QALYs) into the total cost
(in Taiwan dollars, NT$).25 ICER (cost–utility) =
Statistical analysis
Two-way repeated-measures analysis of variance
(ANOVA) was applied to assess the differences
before and after HA treatment. Wilcoxon rank
sum test was used to analyze the differences in
radiographic stages between Artz®- and Synvisc®-
treated knees prior to treatment. Statistical calcu-
lations of the baseline of all scores and the degree
of improvement between Artz®- and Synvisc®-
treated groups were performed by Student’s t
test. The Mann–Whitney U test was used for the
analysis of data concerning (QALYs) and ICER
between the Artz®- and Synvisc®-treated groups.
Statistical significance was set at p < 0.05.
Results
A total of 41 patients met the criteria for inclu-
sion in the study and received the whole treat-
ment course. Thirty-seven patients (mean age,
71.3 ± 7.5 years), including six men (mean age,
74.5 ± 7.4 years) and 31 women (mean age, 70.7 ±
7.5 years), finally completed the 6 months’ 
follow-up, while four patients (9.8%) were with-
drawn from the study for poor compliance with
follow-up. No systemic adverse effects were re-
corded. A few local adverse effects occurred, which
consisted of local pain or swelling of the injec-
tion site, which were relieved after resting. Prior
to treatment, neither radiological staging nor VAS,
WOMAC, WOMAC-A1, Lequesne’s index or HSS
scores showed a significant difference (p > 0.05)
between the Artz®- and Synvisc®-treated groups
(Table).
HA improved clinical symptoms and physical
functions
In two-way repeated-measures ANOVA, none of
the outcome variables had significant interactions
between the drugs and time points (drug × time
total cost NT$
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effects: p > 0.05) (Figure 2). VAS, WOMAC and
Lequesne’s index scores all showed that HA 
significantly decreased the scores in a time-
dependent manner (time effects: p < 0.05), except
for Lequesne’s index scores at week 26. Before
week 16, WOMAC-A1 scores also showed signifi-
cant decreases in a time-dependent manner (time
effects: p < 0.05). HSS scores only showed signifi-
cant improvements before week 12 (time effects:
p < 0.05) and then this effect reached a plateau.
Both VAS and WOMAC-A1 scores showed that
Synvisc® had stronger effects than Artz® (drug 
effects: p < 0.05), whereas WOMAC, Lequesne’s
index and HSS scores did not show significant
differences (drug effects: p = 0.095, p = 0.103 and
p = 0.316, respectively).
Synvisc® had greater pain-relieving effects
and QALY gains
Since Synvisc® had stronger effects than Artz® on
VAS and WOMAC-A1 scores, we further compared
the degree of improvement in the individual HA-
treated knees, and documented these to find the
source of differences between Artz® and Synvisc®
(Figure 3). For VAS scores, Synvisc® showed 
better improvement before week 20 (p < 0.05),
while this effect only appeared at week 12 for the
WOMAC-A1 scores (p < 0.05). Thereafter, two
curves for the utility of Artz® and Synvisc® were
derived from the transformed VAS, and significant
differences in (QALYs) between Artz®- and
Synvisc®-treated groups were observed (p = 0.018;
Figures 4A and 4B).
Synvisc® had better ICER and patient
satisfaction
The payment under the Taiwan National Health
Insurance Program for one Artz® injection was
NT$1415; for one Synvisc® injection, it was
NT$1915, including an intra-articular injection fee
of NT$100 and a clinician fee of NT$213. The cost
of one treatment course of five Artz® injections was
higher than the cost of one treatment course of
three Synvisc® injections (NT$7075 vs. NT$5745).
The direct medical cost for the Taiwan National
Health Insurance Program per QALY gained
(ICER) was NT$7075/0.04101=NT$297,355 [95%
confidence interval (CI): 1,268,650 to 1,863,359) 
for five Artz® injections and NT$5745/0.05977 =
NT$241,456 (95% CI: 1,030,162 to 1,513,074) for
three Synvisc® injections using the transformed
VAS. In addition, the administration fee for each
outpatient clinic visit was NT$460, so the patient
needed to pay NT$2300 for five weekly visits for
Artz® injections and NT$1380 for three weekly
visits for Synvisc® injections. If the patient re-
ceived three Synvisc® injections for one OA knee
rather than five Artz® injections, they could save
NT$920 in total, and reduced the number of vis-
its for the injections by two. The direct medical
Hylan has better efficacy and QALY gain
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Table. Patients’ radiographic evaluation and baseline disease characteristics prior to treatment
Artz® Synvisc® p
Ahlback classification
I 14 11 0.705†
II 16 23
III 7 3
VAS* 68.8 ± 9.7 65.7 ± 8.5 0.148‡
WOMAC* 54.7 ± 14.4 52.7 ± 14.8 0.437‡
WOMAC-A1* 2.7 ± 0.9 2.5 ± 0.8 0.235‡
Lequesne’s index* 15.1 ± 3.6 14.7 ± 3.4 0.596‡
HSS* 70.8 ± 10.8 72.0 ± 9.2 0.595‡
*Results shown as mean ± standard deviation (n = 37); †differences in radiographic stages between Artz®- and Synvisc®-treated groups
(Wilcoxon rank sum test); ‡differences at baseline between Artz®- and Synvisc®-treated groups (Student’s t test). VAS = visual analog
scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; WOMAC-A1 = WOMAC—pain when walking on
a flat surface; HSS = Hospital for Special Surgery.
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Figure 2. (A) VAS (drug × time effects: F = 2.055, p = 0.057; drug effects: F = 9.582, p = 0.003; time effects: F = 84.247,
p < 0.000); (B) WOMAC (drug × time effects: F = 1.621, p = 0.140; drug effects: F = 2.866, p = 0.095; time effects:
F = 131.620, p < 0.000); (C) WOMAC-A1 (drug × time effects: F = 1.047, p = 0.394; drug effects: F = 5.331, p = 0.024;
time effects: F = 84.985, p < 0.000); (D) Lequesne’s index (drug × time effects: F = 1.823, p = 0.093; drug effects:
F = 2.724, p = 0.103; time effects: F = 56.020, p < 0.000); and (E) HSS (drug × time effects: F = 0.388, p = 0.887; drug ef-
fects: F = 1.022, p = 0.316; time effects: F = 15.248, p < 0.000) measured at baseline, the last injection (5 weeks for Artz®
or 3 weeks for Synvisc®), and 8, 12, 16, 20 and 26 weeks after the first injection in both HA-treated knees. Two-way 
repeated-measures ANOVA was used. Values are mean ± standard deviation (n = 37). aSignificantly different, p < 0.05,
when compared with baseline. bSignificantly different, p < 0.05, when compared with the last injection. cSignificantly dif-
ferent, p < 0.05, when compared with 8 weeks. dSignificantly different, p < 0.05, when compared with 12 weeks.
eSignificantly different, p < 0.05, when compared with 16 weeks. fSignificantly different, p < 0.05, when compared with
20 weeks. VAS = visual analog scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index;
WOMAC-A1 = WOMAC—pain when walking on a flat surface; HSS = Hospital for Special Surgery; HA = hyaluronic acid;
ANOVA = analysis of variance. 
cost for the patient per QALY gained (ICER) 
was NT$2300/0.04101 = NT$96,667 (95% CI:
412,423 to 605,757) for five Artz® injections, and
NT$1380/0.05977=NT$58,000 (95% CI: 247,454
to 363,434) for three Synvisc® injections using
the transformed VAS. Without incorporating di-
rect non-medical and indirect costs, the total med-
ical cost for the patient and the Taiwan National
Health Insurance Program per QALY gained (ICER)
was NT$9375/0.04101 = NT$394,021 (95% CI:
1,681,074 to 2,469,116) for five Artz® injections,
and NT$7125/0.05977 = NT$299,456 (95% CI:
1,277,616 to 1,876,529) for three Synvisc® injec-
tions using the transformed VAS. There were also
significant differences between the Artz®- and
Synvisc®-treated groups for ICER for the patient
(p < 0.001), Taiwan National Health Insurance
Program (p = 0.002), and both of these (p = 0.001;
Figures 4C–E). At 26 weeks of follow-up, 31 pa-
tients (83.8%) agreed to receive the same treat-
ment with Artz® injections for their knee OA for
the next course, and 26 of them (83.9%) opted
for three weekly Synvisc® injections.
Discussion
Two well-known characteristics of OA are a con-
sequence of a reduction in molecular size and con-
centration of HA in synovial fluid.26,27 In addition
to the rheological properties, HA with cross-
linked forms can affect its depolymerization and
degradation, and then prolong the MW-dependent
binding ability to specific cell receptors, notably
CD44, which allows HA to modulate cell func-
tion directly and promote downregulation of 
the expression of u-PA, PAI-1, MMP-2 and MMP-
9.5,12,28 This might explain some of the possible
mechanisms for the different clinical efficacy.
Although Artz® has a short intra-articular residence
time (with a half-life < 1 day), a little Synvisc® re-
mains in the synovial fluid 7 days after intra-
articular injection, and significant quantities are
present in the synovial tissue and on the cartilage
surface.7 This is the reason why we did not include
OA knees with significant effusions, which needed
to be aspirated before subsequent injections.
Several cases of pseudoseptic arthritis have
been reported after intra-articular HA injections,
especially Synvisc® injection,29,30 whereas no sys-
temic and few local adverse effects were observed
in the present study. In 6 months of VAS and
WOMAC scores, in 5 months of Lequesne’s index
scores, in 4 months of WOMAC-A1 scores, and
in 3 months of HSS scores, Artz® and Synvisc®
improved clinical symptoms and physical func-
tions. It is therefore reasonable that 31 patients
(83.8%) agreed to receive the same treatment
with HA injections for the next course. As previ-
ously reported, HA with higher MW has a greater
Hylan has better efficacy and QALY gain
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Figure 3. Change in scores in (A) VAS and (B) WOMAC-A1 of both HA-treated knees at the last injection (5 weeks for Artz® or 3 weeks for
Synvisc®), and 8, 12, 16, 20 and 26 weeks after the first injection. Student’s t test was used. Values are mean ± standard deviation (n = 37).
*p < 0.01; †p < 0.05. VAS = visual analog scale; WOMAC-A1 = WOMAC—pain when walking on a flat surface; HA = hyaluronic acid.
effect on the performance of viscosupplementa-
tion.31,32 In the present study, Synvisc® had better
pain-relieving effects, as shown by the VAS scores
at 5 months and of the WOMAC-A1 scores at 12
weeks. Moreover, by injecting Synvisc® instead of
Artz® to treat knee OA, patients saved at least
NT$920 and did not need two additional hospi-
tal visits. This meant savings in both direct costs
and transportation, and they only needed three
injections instead of five. Notably, 83.9% of the
C.W. Chou, et al
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Figure 4. (A) Utilities derived from the transformed VAS of both HA-treated knees at baseline, the last injection, and 8, 12, 16, 20 and 26
weeks after the first injection. (B) Quality of life per period (QALYs) (0–26 weeks) between Artz®- and Synvisc®-treated knees. (C) Direct
medical cost for the Taiwan National Health Insurance Program per QALY gained (ICER) for five Artz® injections and three Synvisc® injec-
tions. (D) Direct medical cost for the patient per QALY gained (ICER) for five Artz® injections and three Synvisc® injections. (E) Total med-
ical cost for the Taiwan National Health Insurance Program and the patient per QALY gained (ICER) for five Artz® injections and three
Synvisc® injections. The Mann–Whitney U test was used (n = 37). VAS = visual analog scale; HA = hyaluronic acid; QALY = quality-adjusted
life year; ICER = incremental cost-effectiveness ratio.
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31 patients who were satisfied with HA treatment
chose Synvisc® for the next course. In addition,
clinicians did not spend time treating the pa-
tients and the Taiwan National Health Insurance
Program did not spend time processing the pay-
ment for the two additional hospital visits.
In the present study, the quality of life per pe-
riod, (QALYs), for Synvisc® was significantly
greater than that for Artz®. Therefore, the direct
medical costs for the Taiwan National Health
Insurance Program and the patient per QALY
gained (ICER) of three Synvisc® injections were
lower than those of five Artz® injections, as were
the total costs for the Taiwan National Health
Insurance Program and the patient. Thus, we sug-
gest that our results are applicable to patients in
Taiwan with early OA of the knee, especially in
terms of cost-effectiveness. Indeed, the data are
still valuable for reference in other countries.
Our study had some limitations. First, there
may be subtle differences in the degree of improve-
ment with the same treatment between different
stages of knee OA. The knees in this study were
not assigned randomly into two groups, and we
divided each pair of knees and compared both of
them. Synvisc® was introduced in Taiwan in 2005;
therefore, there has been little therapeutic experi-
ence in treating knee OA with intra-articular 
injections of Synvisc®. As a result of ethical con-
siderations, the decision to choose five weekly
injections of Artz® or three weekly injections of
Synvisc® for the more painful knee depended on
the patients themselves. The majority of the pa-
tients might have chosen the five weekly Artz® in-
jections for the more painful knee because Artz®
was the most popular option in Taiwan. Never-
theless, no significant differences were found be-
tween these two treated groups before treatment
with regard to radiological staging and all VAS,
WOMAC, WOMAC-A1, Lequesne’s index and HSS
scores. Therefore, their baselines should have been
similar, although the scores in Artz®-treated knees
seemed to be worse than those in Synvisc®-
treated knees.
Second, there is a strong placebo effect from
joint injections, which may cause an approximately
30% reduction in pain relief during the first few
weeks.33 Although we did not have a placebo
group, the placebo effects should be the same for
both treated knees and most should have been
seen in the early periods. Therefore, we believe that
the late findings (4–6 months after the first injec-
tion) of this study should reflect reliable results
for the comparison. Third, we should comment
carefully on a comparison of treatment efficacy
with short-term follow-up and a small sample size.
Under the Taiwan National Health Insurance Pro-
gram, a patient can receive two courses of HA
treatment for one OA knee in 1 year, and we there-
fore designed the 6-month follow-up study on
this basis. However, this result should be validated
in a larger cohort.
In conclusion, our study clearly demonstrated
that both types of viscosupplementation pro-
duced subjective symptom-modifying effects and
an improvement in physical function during a
26-week follow-up period. Synvisc® provided bet-
ter pain relief and reduced the number of hospi-
tal visits for injections by two, as well as reduced
the cost per patient by at least NT$920. Synvisc®
also has better ICER than Artz® for the Taiwan
National Health Insurance Program, the patient,
and both combined. Consequently, injecting HA
to treat knees with early OA is a safe and effica-
cious management for selected patients in Taiwan.
However, further studies are required to better
define the population responsiveness to HA injec-
tions, which may decrease the burden on health-
care systems, and optimize cost-effectiveness as
part of a conservative strategy for OA management.
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